Efficacy and Tolerability of Lacosamide in Pediatric and Young Adult Epilepsy Patients with Severe Motor and Intellectual Disabilities

被引:0
作者
Ishikawa, Nobutsune [1 ]
Suzuki, Shin [1 ]
Komori, Ryota [1 ]
Izumo, Hiroki [1 ]
Goda, Satoshi [1 ]
Tsuboi, Ayana [1 ]
Jinno, Kazuhiko [1 ]
机构
[1] Hiroshima Prefectural Hosp, Dept Pediat, Ujinakanda 1-5-54,Minami Ku, Hiroshima 7348530, Japan
关键词
lacosamide; severe motor and intellectual disabilities; pediatric and young adult; efficacy and tolerability; ADJUNCTIVE THERAPY; OPEN-LABEL; SAFETY; CHILDREN;
D O I
10.1055/a-2508-5990
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objective Epilepsy is common among patients with severe motor and intellectual disabilities (SMID) patients, often taking a prolonged and intractable course. Lacosamide (LCM) is widely used to treat epilepsy in both adults and children. We assess the efficacy and tolerability of LCM among pediatric and young adult epilepsy patients with SMID who suffer from intractable seizures. Methods This retrospective analysis reviewed the medical records of SMID patients undergoing LCM treatment for more than a year. The study included 24 patients (14 males) aged 3 to 29 years. Epilepsy was classified as focal in 17 patients, generalized in 4 patients, and combined generalized and focal in 3 patients. Results The retention rates were 70.8%, 65%, and 52.9% at 1, 2, and 3 years after LCM initiation, respectively. The 50% responder rate (achieving >50% seizure reduction) for LCM treatment was 50%, with two patients experiencing complete seizure control (absence of seizures for 6 months before the follow-up visit). The 50% responders included a higher proportion of patients with focal epilepsy (58.8%) compared to those with generalized epilepsy (25.0%). Treatment-emergent adverse events (TEAEs) included somnolence in five patients and nausea in two patients. TEAEs, particularly nausea, developed within 1 month after treatment initiation in two patients, leading to LCM discontinuation. Conclusion LCM demonstrated good efficacy for intractable epilepsy in pediatric and young adult SMID patients. It was generally well-tolerated, resulting in a favorable retention rate. LCM emerged as a useful antiseizure medication for epilepsy treatment in pediatric and young adult SMID patients.
引用
收藏
页码:119 / 124
页数:6
相关论文
共 27 条
  • [1] Lacosamide in the general population and in people with intellectual disability: Similar responses?
    Allard, Jon
    Henley, William
    Mclean, Brendan
    Sellers, Adrian
    Hudson, Sharon
    Rajakulendran, Sanjeev
    Pace, Adrian
    Pashley, Sarah
    Maguire, Melissa
    Mohan, Monica
    Ellawela, Shan
    Tittensor, Phil
    Ram, Sunil
    Bagary, Manny
    Shankar, Rohit
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2020, 76 : 161 - 166
  • [2] Arima M., 1996, Hattatsu Shogai Kenkyu (Tokyo), V17, P264
  • [3] Efficacy and safety of oral lacosamide as adjunctive therapy in adults with partial-onset seizures
    Ben-Menachem, Elinor
    Biton, Victor
    Jatuzis, Dalius
    Abou-Khalil, Bassel
    Doty, Pamela
    Rudd, G. David
    [J]. EPILEPSIA, 2007, 48 (07) : 1308 - 1317
  • [4] Lacosamide in the treatment of patients with epilepsy and intellectual disabilities: A long-term study of 136 patients
    Boettcher, Stefan
    Lutz, Martin T.
    Mayer, Thomas
    [J]. EPILEPSIA, 2017, 58 (10) : 1749 - 1754
  • [5] Efficacy and tolerability of lacosamide in the concomitant treatment of 130 patients under 16 years of age with refractory epilepsy: A prospective, open-label, observational, multicenter study in Spain
    Carlos Casas-Fernández
    Antonio Martínez-Bermejo
    Miguel Rufo-Campos
    Patricia Smeyers-Durá
    José L. Herranz-Fernández
    Salvador Ibáñez-Micó
    Jaume Campistol-Plana
    Helena Alarcón-Martínez
    Jaime Campos-Castelló
    [J]. Drugs in R&D, 2012, 12 (4) : 187 - 197
  • [6] Enjoji M., 1961, PEDIATR INT, V4, P2, DOI [10.1111/j.1442-200X.1961.tb01032.x, DOI 10.1111/J.1442-200X.1961.TB01032.X]
  • [7] Safety and tolerability of adjunctive lacosamide in a pediatric population with focal seizures - An open-label trial
    Ferreira, Jose A.
    Le Pichon, Jean-Baptiste
    Abdelmoity, Ahmed T.
    Dilley, Deanne
    Dedeken, Peter
    Daniels, Tony
    Byrnes, William
    [J]. SEIZURE-EUROPEAN JOURNAL OF EPILEPSY, 2019, 71 : 166 - 173
  • [8] Prevalence and incidence of epilepsy A systematic review and meta-analysis of international studies
    Fiest, Kirsten M.
    Sauro, Khara M.
    Wiebe, Samuel
    Patten, Scott B.
    Kwon, Churl-Su
    Dykeman, Jonathan
    Pringsheim, Tamara
    Lorenzetti, Diane L.
    Jette, Nathalie
    [J]. NEUROLOGY, 2017, 88 (03) : 296 - 303
  • [9] Efficacy and safety of lacosamide in infants and young children with refractory focal epilepsy
    Grosso, Salvatore
    Parisi, Pasquale
    Spalice, Alberto
    Verrotti, Alberto
    Balestri, Paolo
    [J]. EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY, 2014, 18 (01) : 55 - 59
  • [10] The effect of lacosamide on psychiatric comorbidities in patients with epilepsy
    Hasegawa, Naoya
    Fukuda, Masafumi
    [J]. EPILEPSY & BEHAVIOR REPORTS, 2020, 14